Literature DB >> 10790348

Improvement in exercise capacity with nitric oxide inhalation in patients with precapillary pulmonary hypertension.

T Hasuda1, T Satoh, A Shimouchi, F Sakamaki, S Kyotani, T Matsumoto, Y Goto, N Nakanishi.   

Abstract

BACKGROUND: Patients with precapillary pulmonary hypertension (PH) exhibit a poor exercise capacity due to an impaired vasodilatory response of their pulmonary arteries. By causing the pulmonary artery to dilate, inhaled nitric oxide (NO) may allow an increase in exercise capacity in patients with PH. METHODS AND
RESULTS: On 2 separate days, 3 days apart, 14 patients with precapillary PH (10 primary PH, 4 residual PH after correction of an intracardiac shunt; age, 40+/-12 years; mean pulmonary artery pressure, 60+/-23 mm Hg) performed exercise, with and without inhalation of 20 ppm NO, on a cycle ergometer. The work rate was increased 15 W/min until their symptom-limited maximum, with breath-by-breath gas analysis. Patients were randomly and blindly selected to inhale NO on either their first or second test. Peak exercise load and anaerobic threshold tended to increase, but not significantly. Peak oxygen consumption (f1.gif" BORDER="0">O(2)) and Deltaf1.gif" BORDER="0">O(2)/DeltaW ratio increased significantly, by 18% and 22%, respectively (peak f1.gif" BORDER="0">O(2), 13.6+/-3.6 to 16.0+/-4. 1 mL. kg(-1). min(-1); Deltaf1.gif" BORDER="0">O(2)/DeltaW ratio, 5. 8+/-2.4 to 7.1+/-2.3 mL. kg(-1). min(-1). W(-1); both P<0.01). Peak f1.gif" BORDER="0">O(2) increased >10% in 12 of the 14 patients. However, respiratory quotient at peak exercise decreased from 1. 22+/-0.15 to 1.09+/-0.15 (P<0.01).
CONCLUSIONS: Inhaled NO substantially increases oxygen consumption at the same workload during exercise. This finding supports the possibility of ambulatory NO inhalation therapy in patients with precapillary PH.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10790348     DOI: 10.1161/01.cir.101.17.2066

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  8 in total

1.  Increased consumption and vasodilatory effect of nitrite during exercise.

Authors:  Yuen Yi Hon; Elaina E Lin; Xin Tian; Yang Yang; He Sun; Erik R Swenson; Angelo M Taveira-Dasilva; Mark T Gladwin; Roberto F Machado
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-12-18       Impact factor: 5.464

Review 2.  A review of pulmonary arterial hypertension: Part 2: Current and expected treatments.

Authors:  C T Gan; A Vonk Noordegraaf; K M J Marques; J G F Bronzwaer; P E Postmus; A Boonstra
Journal:  Neth Heart J       Date:  2004-08       Impact factor: 2.380

3.  Medical Gases as an Emerging Topic in Sports Medicine.

Authors:  Sergej M Ostojic
Journal:  Sports Med       Date:  2018-11       Impact factor: 11.136

Review 4.  Endothelin receptor antagonists for pulmonary arterial hypertension.

Authors:  Chao Liu; Junmin Chen; Yanqiu Gao; Bao Deng; Kunshen Liu
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

Review 5.  Pulmonary manifestations of sickle cell disease.

Authors:  A K Siddiqui; S Ahmed
Journal:  Postgrad Med J       Date:  2003-07       Impact factor: 2.401

Review 6.  Pulmonary hypertension: work in progress.

Authors:  Paul D Boyce; Aaron B Waxman
Journal:  J Nucl Cardiol       Date:  2003 Jul-Aug       Impact factor: 5.952

7.  Dehydroepiandrosterone upregulates soluble guanylate cyclase and inhibits hypoxic pulmonary hypertension.

Authors:  Masahiko Oka; Vijaya Karoor; Noriyuki Homma; Tetsutaro Nagaoka; Eiko Sakao; Scott M Golembeski; Jennifer Limbird; Masatoshi Imamura; Sarah A Gebb; Karen A Fagan; Ivan F McMurtry
Journal:  Cardiovasc Res       Date:  2007-02-12       Impact factor: 10.787

8.  Outpatient Inhaled Nitric Oxide in a Patient with Vasoreactive Idiopathic Pulmonary Arterial Hypertension and COVID-19 Infection.

Authors:  Roham T Zamanian; Charles V Pollack; Michael A Gentile; Moira Rashid; John Christian Fox; Kenneth W Mahaffey; Vinicio de Jesus Perez
Journal:  Am J Respir Crit Care Med       Date:  2020-07-01       Impact factor: 21.405

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.